search
Back to results

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Primary Purpose

Healthy Volunteers, Dyslipidaemia

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
NNC0491-6075
Placebo
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy Volunteers

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Part A: Men or women of non-childbearing potential Aged 18-55 years (both inclusive) at the time of signing informed consent Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests (presence of dyslipidaemia [example hypertriglyceridemia] is allowed) performed during the screening visit, as judged by the investigator Body mass index (BMI) between 18.5 and 34.9 kilograms per square meter (kg/m^2) (both inclusive) at screening Non-Japanese defined as not meeting inclusion criteria for Part C Part B: Men or women of non-childbearing potential Aged 18-64 years (both inclusive) at the time of signing informed consent Dyslipidaemia at screening defined as all the below: Fasting serum triglycerides (TGs) greater than or equal to 150 milligrams per deciliter (mg/dL) and less than or equal to 500 mg/dL. Participants must have two measurements performed for eligibility. Both measurements must be greater than or equal to 135 mg/dL and at least one must be greater than or equal to 150 mg/dL. One of the measurements may be based on medical records or pre-screening results if the test is no more than 90 days old. If TGs are measured twice during the screening period, the tests must be performed with at least 4 days apart. TGs measured in the screening period must be after a 10 hour fast Fasting low-density lipoprotein cholesterol (LDL-C) greater than or equal to 50 mg/dL and less than 190 mg/dL Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator BMI between 18.5 and 34.9 kg/m^2 (both inclusive) at screening If on statin therapy the dose must have been stable for at least 8 weeks before screening and must be intended to remain stable throughout the study Part C: Men or women of non-childbearing potential Aged 18-55 years (both inclusive) at the time of signing informed consent Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests (presence of dyslipidaemia [example, hypertriglyceridemia] is allowed) performed during the screening visit, as judged by the investigator BMI between 18.5 and 34.9 kg/m^2 (both inclusive) at screening Japanese defined as both biological parents of Japanese descent Exclusion Criteria: Part A,B and C: Known or suspected hypersensitivity to study intervention(s) or related products Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol Use of prescription or non-prescription medicinal products within 14 days before screening. Exceptions are: Topical medications; occasional use of over-the-counter acetaminophen or Non-steroidal anti-inflammatory drugs (NSAIDs) at their labelled doses for mild pain; and statin therapy in Part B only if the dose has been stable for at least 8 weeks prior to screening and is intended to remain stable throughout the trial Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values: Alanine aminotransferase greater than upper limit of normal (ULN) +50 percentage (%), Aspartate aminotransferase greater than ULN +50%, Total Bilirubin greater than ULN +20%, Creatine kinase greater than ULN +50%.

Sites / Locations

  • Novo Nordisk Investigational SiteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Part A Single ascending dose (SAD) cohorts in healthy participants:

Part B Multiple ascending dose (MAD) cohorts in dyslipidemia participants

Part C: Single ascending dose (SAD) cohorts in healthy Japanese participants:

Arm Description

Healthy participants, randomized in 3:1 ratio in each of the cohorts will receive single ascending dose of either NNC0491-6075 or placebo in 5 cohorts (Cohort A1, A2, A3, A4 and A5). In cohorts A1, A2 and A3, the participants will receive subcutaneous injection, whereas in cohorts A4 and A5 the administration will be performed intravenously.

Participants with dyslipidemia, randomized in the ratio 2:1 in each of the cohorts will receive multiple ascending dose of either NNC0491-6075 or placebo in 3 cohorts (Cohort B1,B2 and B3). Participants will receive subcutaneous injections of either NNC0491-6075 or placebo once weekly for 4 weeks.

Healthy Japanese participants, randomized in the ratio 3:1 in each of the cohorts will receive single ascending dose of either NNC0491-6075 or placebo in 3 cohorts (Cohort C1,C2 and C3). The route of administration will be subcutaneous or intravenous.

Outcomes

Primary Outcome Measures

Part A (SAD): Number of treatment emergent adverse events (TEAEs)
Measured as count of events. An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A TEAE is defined as an AE that either has onset time after first trial product administration and no later than the end of study visit or Is present before first trial product administration and increases in severity during the treatment period and no later than the end of study visit.
Part B (MAD): Number of treatment emergent adverse events (TEAEs)
Measured as count of events. An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A TEAE is defined as an AE that either has onset time after first trial product administration and no later than the end of study visit or Is present before first trial product administration and increases in severity during the treatment period and no later than the end of study visit.
Part C (SAD): Number of treatment emergent adverse events (TEAEs)
Measured as count of events. An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A TEAE is defined as an AE that either has onset time after first trial product administration and no later than the end of study visit or Is present before first trial product administration and increases in severity during the treatment period and no later than the end of study visit.

Secondary Outcome Measures

Part A (SAD): AUC0-∞, SD; the area under the NNC0491-6075 serum concentration-time curve from 0 to infinity after a single dose
Measured as hours*nanomoles per liter (h*nmol/L)
Part A (SAD): Cmax, SD; the maximum serum concentration of NNC0491-6075 after a single dose
Measured as nanomoles per liter (nmol/L)
Part A (SAD): t½, SD; the terminal half-life of NNC0491-6075 after a single dose
Measured as hours (h)
Part A (SAD): tmax, SD; The time to maximum concentration of NNC0491-6075 after a single-dose (only from subcutaneous administration)
Measured as hours
Part B (MAD): AUC0-168h, MD; the area under the NNC0491-6075 serum concentration-time curve from time 0 to 168 hours after last dose
Measured as h*nmol/L
Part B (MAD): Cmax, MD; the maximum serum concentration of NNC0491-6075 after last dose
Measured as nmol/L
Part B (MAD): t½, MD; the terminal half-life of NNC0491-6075 after last dose
Measured as hours
Part B (MAD): tmax, MD; The time to maximum concentration of NNC0491-6075 after last dose
Measured as hours
Part C (SAD): AUC0-∞, SD; the area under the NNC0491-6075 serum concentration-time curve from 0 to infinity after a single dose
Measured as h*nmol/L
Part C (SAD): Cmax, SD; the maximum serum concentration of NNC0491-6075 after a single dose
Measured as nmol/L
Part C (SAD): t½, SD; the terminal half-life of NNC0491-6075 after a single dose
Measured as hours
Part C (SAD): tmax, SD; The time to maximum concentration of NNC0491-6075 after a single-dose (only from subcutaneous administration)
Measured as hours

Full Information

First Posted
July 31, 2023
Last Updated
August 8, 2023
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT05979428
Brief Title
A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood
Official Title
A Phase I, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0491-6075 Following Single Dose Administration to Healthy Participants and Multiple Doses to Participants With Dyslipidaemia
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 7, 2023 (Actual)
Primary Completion Date
February 3, 2025 (Anticipated)
Study Completion Date
March 10, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study is testing a new study medicine to treat people with high levels of fat in the blood. The main aim of the study is to see if the new study medicine is safe and how it works in the body. Participants will either get NNC0491-6075 (the new study medicine) or placebo (a "dummy medicine" without active ingredients). Which treatment participants get is decided by chance. NNC0491-6075 is a new medicine which cannot be prescribed by doctors. The study has 3 parts (Part A, Part B and Part C). In Part A, investigators look at the effect of the study medicine after a single dose in healthy participants. Participants will get the study medicine either as injection(s) under the skin or as an infusion into a vein by the study staff. In Part B, investigators look at the effect of receiving the study medicine once weekly for four weeks in participants with high levels of fat in the blood but who are otherwise healthy. Participants will get the study medicine as injections under the skin by the study staff. In Part C, investigators look at the effect of the study medicine after a single dose in healthy participants of Japanese origin. Participants will get the study medicine either as injection(s) under the skin or as an infusion into a vein by the study staff. The study will last for about 18 months in total for Part A, Part B and Part C. Participants in Part A and Part C will be in the study for about 139 days each, from screening to the final visit while in Part B they will be in the study for about 160 days from screening to the final visit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Volunteers, Dyslipidaemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
106 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part A Single ascending dose (SAD) cohorts in healthy participants:
Arm Type
Experimental
Arm Description
Healthy participants, randomized in 3:1 ratio in each of the cohorts will receive single ascending dose of either NNC0491-6075 or placebo in 5 cohorts (Cohort A1, A2, A3, A4 and A5). In cohorts A1, A2 and A3, the participants will receive subcutaneous injection, whereas in cohorts A4 and A5 the administration will be performed intravenously.
Arm Title
Part B Multiple ascending dose (MAD) cohorts in dyslipidemia participants
Arm Type
Experimental
Arm Description
Participants with dyslipidemia, randomized in the ratio 2:1 in each of the cohorts will receive multiple ascending dose of either NNC0491-6075 or placebo in 3 cohorts (Cohort B1,B2 and B3). Participants will receive subcutaneous injections of either NNC0491-6075 or placebo once weekly for 4 weeks.
Arm Title
Part C: Single ascending dose (SAD) cohorts in healthy Japanese participants:
Arm Type
Experimental
Arm Description
Healthy Japanese participants, randomized in the ratio 3:1 in each of the cohorts will receive single ascending dose of either NNC0491-6075 or placebo in 3 cohorts (Cohort C1,C2 and C3). The route of administration will be subcutaneous or intravenous.
Intervention Type
Drug
Intervention Name(s)
NNC0491-6075
Intervention Description
NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo matched to NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.
Primary Outcome Measure Information:
Title
Part A (SAD): Number of treatment emergent adverse events (TEAEs)
Description
Measured as count of events. An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A TEAE is defined as an AE that either has onset time after first trial product administration and no later than the end of study visit or Is present before first trial product administration and increases in severity during the treatment period and no later than the end of study visit.
Time Frame
From pre-dose (Day 1) to end of study (Day 110)
Title
Part B (MAD): Number of treatment emergent adverse events (TEAEs)
Description
Measured as count of events. An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A TEAE is defined as an AE that either has onset time after first trial product administration and no later than the end of study visit or Is present before first trial product administration and increases in severity during the treatment period and no later than the end of study visit.
Time Frame
From pre-dose (Day 1) to end of study (Day 131)
Title
Part C (SAD): Number of treatment emergent adverse events (TEAEs)
Description
Measured as count of events. An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A TEAE is defined as an AE that either has onset time after first trial product administration and no later than the end of study visit or Is present before first trial product administration and increases in severity during the treatment period and no later than the end of study visit.
Time Frame
From pre-dose (Day 1) to end of study (Day 110)
Secondary Outcome Measure Information:
Title
Part A (SAD): AUC0-∞, SD; the area under the NNC0491-6075 serum concentration-time curve from 0 to infinity after a single dose
Description
Measured as hours*nanomoles per liter (h*nmol/L)
Time Frame
From pre-dose (Day 1) to end of study (Day 110)
Title
Part A (SAD): Cmax, SD; the maximum serum concentration of NNC0491-6075 after a single dose
Description
Measured as nanomoles per liter (nmol/L)
Time Frame
From pre-dose (Day 1) to end of study (Day 110)
Title
Part A (SAD): t½, SD; the terminal half-life of NNC0491-6075 after a single dose
Description
Measured as hours (h)
Time Frame
From pre-dose (Day 1) to end of study (Day 110)
Title
Part A (SAD): tmax, SD; The time to maximum concentration of NNC0491-6075 after a single-dose (only from subcutaneous administration)
Description
Measured as hours
Time Frame
From pre-dose (Day 1) to end of study (Day 110)
Title
Part B (MAD): AUC0-168h, MD; the area under the NNC0491-6075 serum concentration-time curve from time 0 to 168 hours after last dose
Description
Measured as h*nmol/L
Time Frame
From pre-dose (Day 22) to 168 hours after last dose (Day 29)
Title
Part B (MAD): Cmax, MD; the maximum serum concentration of NNC0491-6075 after last dose
Description
Measured as nmol/L
Time Frame
From pre-dose (Day 22) to end of study (Day 131)
Title
Part B (MAD): t½, MD; the terminal half-life of NNC0491-6075 after last dose
Description
Measured as hours
Time Frame
From pre-dose (Day 22) to end of study (Day 131)
Title
Part B (MAD): tmax, MD; The time to maximum concentration of NNC0491-6075 after last dose
Description
Measured as hours
Time Frame
From pre-dose (Day 22) to end of study (Day 131)
Title
Part C (SAD): AUC0-∞, SD; the area under the NNC0491-6075 serum concentration-time curve from 0 to infinity after a single dose
Description
Measured as h*nmol/L
Time Frame
From pre-dose (Day 1) to end of study (Day 110)
Title
Part C (SAD): Cmax, SD; the maximum serum concentration of NNC0491-6075 after a single dose
Description
Measured as nmol/L
Time Frame
From pre-dose (Day 1) to end of study (Day 110)
Title
Part C (SAD): t½, SD; the terminal half-life of NNC0491-6075 after a single dose
Description
Measured as hours
Time Frame
From pre-dose (Day 1) to end of study (Day 110)
Title
Part C (SAD): tmax, SD; The time to maximum concentration of NNC0491-6075 after a single-dose (only from subcutaneous administration)
Description
Measured as hours
Time Frame
From pre-dose (Day 1) to end of study (Day 110)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Part A: Men or women of non-childbearing potential Aged 18-55 years (both inclusive) at the time of signing informed consent Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests (presence of dyslipidaemia [example hypertriglyceridemia] is allowed) performed during the screening visit, as judged by the investigator Body mass index (BMI) between 18.5 and 34.9 kilograms per square meter (kg/m^2) (both inclusive) at screening Non-Japanese defined as not meeting inclusion criteria for Part C Part B: Men or women of non-childbearing potential Aged 18-64 years (both inclusive) at the time of signing informed consent Dyslipidaemia at screening defined as all the below: Fasting serum triglycerides (TGs) greater than or equal to 150 milligrams per deciliter (mg/dL) and less than or equal to 500 mg/dL. Participants must have two measurements performed for eligibility. Both measurements must be greater than or equal to 135 mg/dL and at least one must be greater than or equal to 150 mg/dL. One of the measurements may be based on medical records or pre-screening results if the test is no more than 90 days old. If TGs are measured twice during the screening period, the tests must be performed with at least 4 days apart. TGs measured in the screening period must be after a 10 hour fast Fasting low-density lipoprotein cholesterol (LDL-C) greater than or equal to 50 mg/dL and less than 190 mg/dL Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator BMI between 18.5 and 34.9 kg/m^2 (both inclusive) at screening If on statin therapy the dose must have been stable for at least 8 weeks before screening and must be intended to remain stable throughout the study Part C: Men or women of non-childbearing potential Aged 18-55 years (both inclusive) at the time of signing informed consent Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests (presence of dyslipidaemia [example, hypertriglyceridemia] is allowed) performed during the screening visit, as judged by the investigator BMI between 18.5 and 34.9 kg/m^2 (both inclusive) at screening Japanese defined as both biological parents of Japanese descent Exclusion Criteria: Part A,B and C: Known or suspected hypersensitivity to study intervention(s) or related products Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol Use of prescription or non-prescription medicinal products within 14 days before screening. Exceptions are: Topical medications; occasional use of over-the-counter acetaminophen or Non-steroidal anti-inflammatory drugs (NSAIDs) at their labelled doses for mild pain; and statin therapy in Part B only if the dose has been stable for at least 8 weeks prior to screening and is intended to remain stable throughout the trial Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values: Alanine aminotransferase greater than upper limit of normal (ULN) +50 percentage (%), Aspartate aminotransferase greater than ULN +50%, Total Bilirubin greater than ULN +20%, Creatine kinase greater than ULN +50%.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Novo Nordisk
Phone
(+1) 866-867-7178
Email
clinicaltrials@novonordisk.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Transparency dept. 2834
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Cypress
State/Province
California
ZIP/Postal Code
90630
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
IPD Sharing URL
http://novonordisk-trials.com

Learn more about this trial

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

We'll reach out to this number within 24 hrs